Clinical and Pharmacokinetic Studies on the New Platinum Complex Zeniplatin (CL286,558)

  • D. de Valeriola
  • A. Forrest
  • P. Dodion
  • N. Crespeigne
  • M. Piccart
  • R. Rastogi
  • J. D. Kantrowitz
  • M. J. Egorin

Abstract

In an effort to develop more active and less toxic analogues of cisplatin, zeniplatin (code number: CL 286,558; [2, 2-Bis (aminomethyl)-1, 3-propanediol-N,N′] [1, 1-cyclobutane dicarboxylato]-(2-) -0,0′] Platinum (Pt)) has been synthesized (American Cyanamid Company, Pearl River, NY). This new agent has a molecular weight of 471.38 and is much more water soluble than cisplatin. The compound was selected for a phase I clinical and pharmacokinetic trial on the basis of its high therapeutic index and its broad spectrum of antitumor activity against human xenografts implanted in nude mice and murine solid tumor models. Its activity against B16 melanoma and M5076 reticulum cell sarcoma murine tumor models is higher than for both cisplatin and carboplatin1,2. In animal models, zeniplatin was found to be less myelosuppressive and nephrotoxic than cisplatin at therapeutic dosage. The exact mechanism of action of this compound has not been elucidated yet2. We here report the results of the phase I clinical trial performed at the Institut Jules Bordet and of the preliminary pharmacokinetic studies. Since other Pt analogues are known to extensively bind to plasma proteins, an in vitro study of the rate and extent of protein binding was also accomplished.

Keywords

High Therapeutic Index Protein Binding Study Bayesian Prior Flameless Atomic Absorption Spectrophotometry American Cyanamid Company 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    F. E. Durr, S. G. Carvajal, and R. E. Wallace, Two new platinum complexes with significant antitumor activity in mice. Proc 6th NCII-EORTC Symp on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, Abs 198 (1989).Google Scholar
  2. 2.
    Clinical Brochure for Investigators, American Cyanamid Company, Pearl River, New York (1989).Google Scholar
  3. 3.
    WHO Handbook for reporting results of cancer treatment, WHO, Geneva (1979).Google Scholar
  4. 4.
    Z. H. Siddik, M. Jones, F. E. Boxall, and K. R. Harrap, Comparative distribution and excretion of carboplatin and cisplatin in mice, Cancer Chemother Pharmacol 21:19 (1988).PubMedCrossRefGoogle Scholar
  5. 5.
    R. C. Gaver, A. M. George, G. F. Duncan, A. D. Morris, G. Deeb, H. C. Faulkner, R. H. Farmen, The disposition of carboplatin in the beagle dog, Cancer Chemother Pharmacol 21:197 (1988).PubMedCrossRefGoogle Scholar
  6. 6.
    S. Oguri, T. Sakakibara, H. Masa, T. Shimizu, K. Ishikawa, K. Kimura, R. D. Smith, Clinical pharmacokinetics of carboplatin, J Clin Pharmacol 28:208 (1988).PubMedCrossRefGoogle Scholar
  7. 7.
    L. B. Sheiner, S. L. Beal, B. Rosenberg, and V. Marathe, Forecasting individual pharmacokinetics, Clin Pharmacol Ther 26:295 (1979).Google Scholar
  8. 8.
    L. B. Sheiner, and S. L. Beal, Bayesian individualisation of pharmacokinetics: simple implementation and comparison with non-Bayesian methods, J Pharm Sci 71:1344 (1982).PubMedCrossRefGoogle Scholar
  9. 9.
    D. Z. D’Argenio, and A. Schumitzky, A program package for simulation and parameter estimation in pharmacokinetic systems. Comp Programs Biomed 9:115 (1979).CrossRefGoogle Scholar
  10. 10.
    K. Yamaoka, T. Nakagawa, and T. Uno, Application of Akaike’s information criterion in the evaluation of linear pharmacokinetic equations. J Pharmacokin Biopharm 6:165 (1978).CrossRefGoogle Scholar
  11. 11.
    F. F. Farris, F. G. King, R. L. Dedrick, and C. L. Litterst, Physiological model for the pharmacokinetics of cis-dichlorodiammineplatinum (II) (DDP) in the tumored rat. J Pharmacokinetics Biopharm 13:13 (1985).CrossRefGoogle Scholar
  12. 12.
    R. C. Gaver, N. Colombo, M. D. Green, A. M. George, G. Deeb, A. D. Morris, R. M. Canetta, J. L. Speyer, R. H. Farmen, F. M. Muggia, The disposition of carboplatin in ovarian cancer patients, Cancer Chemother Pharmacol 22:263 (1988).PubMedCrossRefGoogle Scholar
  13. 13.
    E. Reed and K. W. Kohn, Platinum Analogues, in: Cancer Chemotherapy: Principles and Practice, B. A. Chabner and J. M. Collins, eds., J. B. Lippincott Company, Philadelphia (1990).Google Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • D. de Valeriola
    • 1
    • 2
  • A. Forrest
    • 2
  • P. Dodion
    • 1
  • N. Crespeigne
    • 1
  • M. Piccart
    • 1
  • R. Rastogi
    • 3
  • J. D. Kantrowitz
    • 3
  • M. J. Egorin
    • 2
  1. 1.Institut Jules BordetBrusselsBelgium
  2. 2.University of Maryland Cancer CenterBaltimoreUSA
  3. 3.Medical Research DivisionAmerican Cyanamid CompanyPearl RiverUSA

Personalised recommendations